Agilent Partners with University of Michigan for Prostate Cancer Research
Apr 15, 2009
Agilent Technologies (Santa Clara, California) announced its support of prostate cancer research by the University of Michigan’s (Ann Arbor) Center for Translational Pathology through a grant of instruments and funding. The goal is to accelerate research to defeat the disease using a multidisciplinary systems biology approach. The company is contributing a 1200 Series liquid chromatography (LC) system to be used to separate metabolites from human plasma as well as a 1200 Series Rapid Resolution LC system coupled to a model 6530 Accurate Mass quadrupole time-of-flight mass spectrometer for the identification of those metabolites.
Rate this page
Your original vote has been tallied and is included in the ratings results.
Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: Seven Common Faux Pas in Modern HPLC